Follicular Lymphoma
📧 Sign up to get email alerts when something new happens for Follicular Lymphoma.
Sign up freeTop drugs studied for this disease
-
EMA approval · 2026-08-06EMA Authorised: Breyanzi (lisocabtagene maraleucel) — Bristol-Myers Squibb Pharma EEIG
The EMA has authorised Breyanzi (lisocabtagene maraleucel) for specified lymphomas, including large B-cell diffuse and follicular lymphoma, …
-
EMA approval · 2026-07-02EMA Authorised: Lunsumio (mosunetuzumab) — Roche Registration GmbH
The EMA authorises Lunsumio (mosunetuzumab) from Roche Registration GmbH for follicular lymphoma with conditional approval and orphan design…
-
EMA approval · 2026-06-08EMA Authorised: Yescarta (axicabtagene ciloleucel) — Kite Pharma EU B.V.
The EMA authorises Yescarta (axicabtagene ciloleucel) for certain lymphomas, indicating market authorization and orphan designation.
-
CLINICAL_TRIALS trial_result · 2026-04-24Clinical Trial Update: Anti-CD22 Chimeric Receptor T Cells in Pediatric and Young Adults With Recurrent or Refractory CD22-expressing B Cell Malignancies [Phase 1]
Phase 1 trial evaluating anti-CD22 CAR T cells in pediatric and young adult patients with recurrent or refractory CD22-expressing B-cell mal…
-
CLINICAL_TRIALS research · 2026-04-24Clinical Trial Update: Clonal Evolution in Follicular Lymphoma
The clinical trial is currently recruiting to study clonal evolution in follicular lymphoma.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2026-04-24Clinical Trial Update: Sonrotoclax, Zanubrutinib and Rituximab in Previously Untreated Patients With Follicular Lymphoma [Phase 2]
A Phase 2 clinical trial is evaluating Sonrotoclax in combination with Zanubrutinib and Rituximab for previously untreated Follicular Lympho…
-
CLINICAL_TRIALS research · 2026-04-23Clinical Trial Update: Orelabrutinib Plus Rituximab Followed by Maintenance With Orelabrutinib for Relapsed and Refractory Follicular Lymphoma(RR FL) [Phase 2]
Phase 2 trial assessing orelabrutinib in combination with rituximab, followed by orelabrutinib maintenance, for relapsed and refractory foll…
-
CLINICAL_TRIALS trial_result · 2026-04-23Clinical Trial Update: A Clinical Study Exploring the Safety, Efficacy and Metabolic Kinetics of CT1182 Injection in Patients With Relapsed / Refractory Non Hodgkin Lymphoma [EARLY_Phase 1]
Early-phase clinical trial update on the safety, efficacy and metabolic kinetics of CT1182 injection in relapsed/refractory non-Hodgkin lymp…
-
CLINICAL_TRIALS research · 2026-04-23Clinical Trial Update: Mosunetuzumab Consolidation Therapy After autoSCT in r/r Aggressive B Cell Lymphoma [Phase 1]
Phase 1 clinical trial evaluating mosunetuzumab consolidation after autologous stem cell transplantation in relapsed/refractory aggressive B…
-
CLINICAL_TRIALS trial_result · 2026-04-22Clinical Trial Update: Testing the Safety of the Anti-cancer Drugs Tazemetostat and Belinostat in Patients With Lymphomas That Have Resisted Treatment [Phase 1]
Phase 1 trial to assess the safety of the anti-cancer drugs tazemetostat and belinostat in patients with recurrent or refractory lymphomas; …
-
CLINICAL_TRIALS research · 2026-04-22Clinical Trial Update: Clinical Study of XNW5004 Tablets in the Treatment of Relapsed and Refractory Follicular Lymphoma [Phase 2]
A Phase 2 clinical trial of XNW5004 Tablets for relapsed and refractory follicular lymphoma is currently recruiting.
-
CLINICAL_TRIALS research · 2026-04-22Clinical Trial Update: A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies [Phase 1, Phase 2]
This is a Phase 1/2 dose-escalation and expansion study of BGB-16673 in patients with various B-cell malignancies and is currently recruitin…
-
CLINICAL_TRIALS other · 2026-04-22Clinical Trial Update: A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma [Phase 3]
Clinical Trial Update describing a Phase 3 study comparing Zanubrutinib plus anti-CD20 therapy versus Lenalidomide plus Rituximab in relapse…
-
CLINICAL_TRIALS research · 2026-04-22Clinical Trial Update: Pirtobrutinib and Mosunetuzumab for the Treatment of Relapsed/Refractory Grades 1-3A Follicular Lymphoma, PROMOTE-FL Trial [Phase 2]
This Phase 2 trial (PROMOTE-FL) evaluates pirtobrutinib in combination with mosunetuzumab for relapsed/refractory follicular lymphoma and is…
-
CLINICAL_TRIALS trial_result · 2026-04-21Clinical Trial Update: Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma [Phase 3]
Phase 3 clinical trial comparing rituximab and mosunetuzumab for low tumor burden follicular lymphoma is currently recruiting.
-
CLINICAL_TRIALS research · 2026-04-20Clinical Trial Update: Zanubrutinib in Combination With Sonrotoclax for the Treatment of Underrepresented Ethnic and Racial Minorities With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma [Phase 1]
Phase 1 clinical trial update evaluating zanubrutinib in combination with sonrotoclax for relapsed or refractory B-cell non-Hodgkin lymphoma…
-
CLINICAL_TRIALS research · 2026-04-20Clinical Trial Update: A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituximab Versus Placebo in Combination With Lenalidomide Plus Rituximab in Adult Patients at Least 18 Years of Age With Relapsed/Refractory Follicular Lymphoma. [Phase 3]
A Phase 3 trial evaluating Tazemetostat in combination with Lenalidomide and Rituximab versus placebo with Lenalidomide and Rituximab in adu…
-
CLINICAL_TRIALS trial_result · 2026-04-17Clinical Trial Update: Gazyvaro and Low Dose Radiotherapy in Early Stage Follicular Lymphoma [Phase 2]
Phase 2 study of Gazyvaro (obinutuzumab) with low-dose radiotherapy in early-stage follicular lymphoma has completed.
-
CLINICAL_TRIALS research · 2026-04-17Clinical Trial Update: A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers [Phase 1]
This is a Phase 1 clinical trial update for LY4584180 in adults with previously treated blood cancers, including Non-Hodgkin lymphoma, diffu…
-
CLINICAL_TRIALS research · 2026-04-17Clinical Trial Update: A Study of Surovatamig (AZD0486) Plus Rituximab in Previously Untreated Follicular Lymphoma Patients [Phase 3]
Phase 3 clinical trial evaluating Surovatamig (AZD0486) in combination with Rituximab for previously untreated follicular lymphoma; currentl…
-
CLINICAL_TRIALS research · 2026-04-17Clinical Trial Update: Treatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein-Degrader [Phase 1, Phase 2]
Ongoing Phase 1/2 clinical trial update for BGB-16673, a BTK-targeted protein degrader, in Chinese participants with various B-cell malignan…
-
CLINICAL_TRIALS research · 2026-04-17Clinical Trial Update: A Phase III Trial Comparing Tisagenlecleucel to Standard of Care (SoC) in Adult Participants With r/r Follicular Lymphoma [Phase 3]
Novartis is conducting a Phase 3 trial comparing tisagenlecleucel to standard of care in adults with relapsed/refractory follicular lymphoma…
-
CLINICAL_TRIALS research · 2026-04-16Clinical Trial Update: A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma [Phase 1]
Pfizer is conducting a Phase 1 study of mevrometostat for relapsed/refractory small cell lung cancer, metastatic castration-resistant prosta…
-
CLINICAL_TRIALS trial_result · 2026-04-16Clinical Trial Update: Acalabrutinib, Lenalidomide, and Rituximab for the Treatment of CD20 Positive Stage III-IV, Grade 1-3a Follicular Lymphoma [Phase 2]
Phase 2 trial at MD Anderson evaluating a combination of acalabrutinib, lenalidomide, and rituximab for CD20-positive follicular lymphoma at…
-
CLINICAL_TRIALS research · 2026-04-15Clinical Trial Update: Autologous Stem Cell Transplant Followed by Polatuzumab Vedotin in Patients With B-cell Non-Hodgkin and Hodgkin Lymphoma [Phase 1, Phase 2]
A Phase 1/2 clinical trial update describes autologous stem cell transplant followed by polatuzumab vedotin for patients with various B-cell…